Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
317.09
+2.92 (0.93%)
At close: Nov 20, 2024, 4:00 PM
320.00
+2.91 (0.92%)
Pre-market: Nov 21, 2024, 4:14 AM EST
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 376 employees as of December 31, 2023. The number of employees increased by 284 or 308.70% compared to the previous year.
Employees
376
Change (1Y)
284
Growth (1Y)
308.70%
Revenue / Employee
$204,290
Profits / Employee
-$1,379,441
Market Cap
6.92B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 376 | 284 | 308.70% |
Dec 31, 2022 | 92 | 21 | 29.58% |
Dec 31, 2021 | 71 | 29 | 69.05% |
Dec 31, 2020 | 42 | 13 | 44.83% |
Dec 31, 2019 | 29 | 12 | 70.59% |
Dec 31, 2018 | 17 | 9 | 112.50% |
Dec 31, 2017 | 8 | 0 | - |
Dec 31, 2016 | 8 | -2 | -20.00% |
Dec 31, 2015 | 10 | -100 | -90.91% |
Dec 31, 2014 | 110 | -24 | -17.91% |
Dec 31, 2013 | 134 | 10 | 8.06% |
Dec 31, 2012 | 124 | 2 | 1.64% |
Dec 31, 2011 | 122 | 10 | 8.93% |
Dec 31, 2010 | 112 | -15 | -11.81% |
Dec 31, 2009 | 127 | -2 | -1.55% |
Dec 31, 2008 | 129 | -46 | -26.29% |
Dec 31, 2007 | 175 | 29 | 19.86% |
Dec 31, 2006 | 146 | 28 | 23.73% |
Jan 12, 2005 | 118 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Jazz Pharmaceuticals | 2,800 |
Legend Biotech | 1,826 |
Repligen | 1,783 |
MDGL News
- 15 days ago - Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
- 20 days ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® - GlobeNewsWire
- 24 days ago - Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings - Seeking Alpha
- 27 days ago - Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings - Seeking Alpha
- 4 weeks ago - Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis - GlobeNewsWire
- 4 weeks ago - Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 - GlobeNewsWire